Last quarter (Q3 2025), CytomX Therapeutics's total revenue was $5.96M, a decrease of -82.16% from the same quarter last year. In Q3, CytomX Therapeutics's net income was $-14.23M. See CytomX Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 138.10M	$ 101.21M	$ 53.16M	$ 37.31M	$ 68.43M
Gross Profit	$ 138.10M	$ 101.21M	$ 53.16M	$ 37.31M	$ 68.43M
Operating Expenses	$ 113.11M	$ 107.70M	$ 154.50M	$ 153.35M	$ 148.97M
Depreciation and Amortization	$ 1.77M	$ 2.17M	$ 2.44M	$ 2.71M	$ 2.57M
EBITDA	$ 26.76M	$ -4.31M	$ -98.89M	$ -113.34M	$ -77.97M
Operating Income	$ 25.00M	$ -6.48M	$ -101.33M	$ -116.04M	$ -80.54M
Other Income/Expenses	$ 7.10M	$ 9.81M	$ 2.02M	$ 172.00K	$ 29.63M
Pretax Income	$ 32.09M	$ 3.32M	$ -99.32M	$ -115.87M	$ -50.91M
Net Income	$ 31.87M	$ -569.00K	$ -99.32M	$ -115.87M	$ -64.82M
Per Share Metrics
Basic EPS	$ 0.38	$ -0.01	$ -1.48	$ -1.26	$ -0.71
Diluted EPS	$ 0.38	$ -0.01	$ -1.48	$ -1.26	$ -0.71
Weighted Average Shares Outstanding	84.44M	73.81M	65.74M	64.15M	46.15M
Weighted Average Shares Outstanding (Diluted)	84.75M	73.81M	65.74M	64.15M	46.15M

Currency in USD

CytomX Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing